AERI - Aerie Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real-time price. Currency in USD
32.28
-0.61 (-1.87%)
As of 1:34PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close32.89
Open33.26
Bid32.20 x 800
Ask32.29 x 800
Day's range32.06 - 33.65
52-week range31.01 - 74.75
Volume225,783
Avg. volume560,382
Market cap1.482B
Beta (3Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-5.53
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est77.60
Trade prices are not sourced from all markets
  • Business Wire3 days ago

    Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr. Calabrese will lead external financial reporting, technical accounting and equity accounting. In connection with his acceptance of the position as Director of Accounting, Mr. Calabrese will receive awards totaling 14,400 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.

  • Business Wire9 days ago

    Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the trea

  • Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price?
    Simply Wall St.14 days ago

    Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price?

    Anyone researching Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) might want to consider the historical volatility of the...

  • Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?
    Zacks14 days ago

    Why Is Aerie (AERI) Down 10.2% Since Last Earnings Report?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire23 days ago

    Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 2:30 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
    Zackslast month

    Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint

    Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.

  • Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates
    Zackslast month

    Aerie (AERI) Q1 Earnings Beat, Rhopressa Misses Estimates

    Aerie (AERI) reports narrower-than-expected Q1 loss. However, Rhopressa lags expectations.

  • Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript
    Motley Foollast month

    Aerie Pharmaceuticals, Inc. (AERI) Q1 2019 Earnings Call Transcript

    AERI earnings call for the period ending March 31, 2019.

  • Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates
    Zackslast month

    Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates

    Aerie (AERI) delivered earnings and revenue surprises of 14.29% and -14.27%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Aerie: 1Q Earnings Snapshot

    The North Carolina, North Carolina-based company said it had a loss of $1.06 per share. Losses, adjusted for non-recurring costs, came to 78 cents per share. The results exceeded Wall Street expectations. ...

  • Business Wirelast month

    Aerie Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Business Update

    Conference Call and Webcast Today, May 7th, at 5:00 p.m. ET

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces Additional Undrawn $100M Credit Facility with Deerfield Management, Increasing Availability to $200M

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has entered into an amendment of its existing credit agreement with certain affiliates of Deerfield Management Company L.P. (Deerfield). The amendment provides for an additional $100 million senior secured delayed draw term loan facility (the additional credit facility), pursuant to which Aerie may borrow up to $100 million in aggregate in one or more borrowings at any time on or prior to July 23, 2020. Amounts drawn under the additional credit facility will amortize in equal annual installments beginning on July 20, 2023 and will mature on July 23, 2024.

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces U.S. Launch of Rocklatan® and Increase in Rhopressa® Medicare Part D Coverage to Approximately 75% of Lives

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it has launched Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% into the United States glaucoma market. Rocklatan® is now with national and regional U.S. pharmaceutical wholesalers, and patients can fill prescriptions for Rocklatan® through their local pharmacies across the nation. Additionally, effective May 1, Medicare Part D preferred tier coverage for Rhopressa® (netarsudil ophthalmic solution) 0.02% increased from approximately 40% to 75%.

  • Business Wire2 months ago

    Aerie Pharmaceuticals to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye announced today that its first quarter 2019 financial results will be released after the market closes on Tuesday, May 7, 2019. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com.

  • Business Wire2 months ago

    Aerie Pharmaceuticals Announces Acceptance of Its Investigational New Drug Application for AR-13503 Sustained Release Implant

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has reviewed the Investigational New Drug Application (IND) for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant (the AR-13503 implant) and it is now in effect, allowing Aerie to initiate human studies in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The IND was submitted in March 2019.

  • Have Insiders Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares This Year?
    Simply Wall St.2 months ago

    Have Insiders Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares This Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak perf...

  • Business Wire3 months ago

    Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 18th Annual Needham Healthcare Conference on Tuesday, April 9, 2019 at 1:30 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Business Wire3 months ago

    Aerie Pharmaceuticals Announces Appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Gianluca Corbinelli as Chief Commercial Officer - Europe, reporting to Thomas Mitro, Aerie’s President and Chief Operating Officer. Mr. Corbinelli will be responsible for overseeing the execution of all aspects of Aerie’s commercialization activities in Europe, to develop the commercial infrastructure necessary to support Aerie’s business plans in Europe including ultimately the successful commercialization of products in the region upon their approval.

  • Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?
    Zacks3 months ago

    Aerie (AERI) Improves 22% YTD: Is Momentum Likely to Sustain?

    Aerie (AERI) gains momentum on the back of the FDA approval of its second drug, Rocklatan.

  • Aerie (AERI) Down 2.9% Since Last Earnings Report: Can It Rebound?
    Zacks3 months ago

    Aerie (AERI) Down 2.9% Since Last Earnings Report: Can It Rebound?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire3 months ago

    Aerie Pharmaceuticals Announces Four Appointments

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of David Ellis, Ph.D., as Director, Chemistry, reporting to Mitchell deLong, Ph.D., Aerie’s Vice President of Chemistry. Dr. Ellis will be responsible for advancing the Company’s creation and optimization of new chemical entities to support the growth and advancement of Aerie’s pipeline. Dr. Ellis most recently held a related position at Novartis.

  • Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
    Zacks3 months ago

    Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan

    Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

  • Business Wire3 months ago

    Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States and is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

  • Business Wire3 months ago

    Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion

    Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This Phase 2 study (AR1105-CS201) will be conducted at approximately 20 centers in the United States and enroll up to 45 patients. In the initial safety stage, up to 5 patients will be enrolled in a single cohort to receive clinical formulation #1 (CF-1), delivering a 340µg dose of dexamethasone in a single intravitreal injection.

  • Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
    Zacks3 months ago

    Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma

    Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes